A Phase II Exploratory Study of PXD-101(Belinostat) Followed by Zevalin in Patients With Relapsed Aggressive High-Risk Lymphoma

Trial Profile

A Phase II Exploratory Study of PXD-101(Belinostat) Followed by Zevalin in Patients With Relapsed Aggressive High-Risk Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Belinostat (Primary) ; Ibritumomab tiuxetan; Rituximab
  • Indications Anaplastic large cell lymphoma; B cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Apr 2016 Planned End Date changed from 1 Jan 2016 to 1 Dec 2020.
    • 13 Apr 2016 Status changed from recruiting to active, no longer recruiting.
    • 01 Dec 2015 Planned End Date changed from 1 Mar 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top